Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Часто задаваемые вопросы
В каком секторе работает Adaptive Biotechnologies Corporation (ADPT)?
Adaptive Biotechnologies Corporation относится к сектору Здравоохранение.
Какова текущая цена акций Adaptive Biotechnologies Corporation (ADPT)?
По последним данным, цена акций Adaptive Biotechnologies Corporation составляет 25,16 $, предыдущее закрытие — 24,78 $. За последнюю торговую сессию акции Adaptive Biotechnologies Corporation выросли на 0,38 $, что соответствует росту на 1,53%.
Выплачивает ли Adaptive Biotechnologies Corporation (ADPT) дивиденды?
Нет, Adaptive Biotechnologies Corporation не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Adaptive Biotechnologies Corporation (ADPT)?
У компании Adaptive Biotechnologies Corporation бета 2.072, что свидетельствует о крайне высокой волатильности по сравнению с рынком
